Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

Berlin: Bayer has submitted an application to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval of ...

Bayer’s consumer health business benefits from a narrow economic moat, largely because of its strong brand power. Consumers continue to pay a premium for Aspirin, Aleve, and other over-the-counter ...

Thanks to hefty sales increases from kidney disease drug Kerendia and prostate cancer treatment Nubeqa, Bayer’s pharma ...

EBITDA before special items decreases to 4.085 billion euros (minus 7.4 percent) / Moderate decline in sales (Fx & p adj.) at ...

Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ETCompany ParticipantsBill Anderson - Chairman & CEOWolfgang Nickl ...

Bayer’s strong first quarter performance was mainly driven by its pharmaceuticals division, even as its crop-science branch ...

Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen ...

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where ...

Bayer chief executive Bill Anderson has said that newer product launches have offset the decline in sales of anticoagulant ...

Bayer said an adverse verdict in a US glyphosate lawsuit, which it is appealing against, had added to litigation costs. The company has also filed a petition with the US Supreme Court and has ...

We recently compiled a list of the 10 Jim Cramer Stocks with Huge Upside Potential. In this article, we are going to take a ...